Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

With $173 million, new startup takes aim at sickle cell

STAT NewsView source article

Part of story

Marrow raises $173M to develop siRNA alternative to gene therapy for sickle cell

Startup Marrow Therapeutics raised $173 million to develop an siRNA-based infusion therapy for sickle cell disease and beta thalassemia, positioning it as a more accessible alternative to approved one-time CRISPR and gene therapy treatments.

Nov 17, 2026·3 sourcesBiotech innovationGene therapyDrug developmentHematologyBiotechnologyBiotech startupGenetic disordersVenture capital funding
Marrow raises $173M to develop siRNA alternative to gene therapy for sickle cell
00

Other sources for this story

BioPharma Dive

Marrow sets out to challenge genetic medicines for severe blood diseases

Endpoints

Marrow raises $173M for siRNA drug to compete with one-time CRISPR therapy for sickle cell